The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InPfizer, Merck, and Astellas Pharma have announced successful Phase 3 trial results for their combination therapy targeting muscle-invasive bladder cancer. The clinical trial, known as EV-304/KEYNOTE-B15, demonstrated that the combination of PADCEV and Keytruda significantly improves survival outcomes. Data showed a 47% reduction in the risk of disease recurrence or death compared to standard chemotherapy. Furthermore, the treatment resulted in a 35% reduction in the overall risk of death for patients eligible for cisplatin-based therapy both before and after surgery. These strong results strengthen the market position of all three pharmaceutical giants in the high-growth oncology sector. The successful trial is expected to expand the indications for these high-revenue drugs, potentially boosting future revenue streams.